Circadian concepts in normal and neoplastic breast

REFERENCES

• Moller-Jensen O., Estève J., Moller H., Renard H. Cancer in the European Community and Its Member States. Eur. J. Cancer 1990; 11/12: 1167–1256
   Google Scholar
• Parkin D.M., Muir C.S., Whelan S.L., Gao S.T., Ferlay J., Powell J. Cancer Incidence in Five Continents. IARC Sci. Publ. 1992; 6(120)
   Google Scholar
• Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer Statistics. CA Cancer J. Clin. 1999; 49(1)8–31
   PubMed Web of Science ®Google Scholar
• Paterson A.H.G., Szafran O., Hanson J. Response to Treatment and Its Influence on Survival in Metastatic Breast Cancer. Am. J. Clin. Oncol. 1985; 8: 283–292
   PubMed Web of Science ®Google Scholar
• Greenberg P.A.C., Hortobagyi G.N., Smith T.L., Ziegler L.D., Frye D.K., Buzdar A.U. Long-Term Follow Up of Patients with Complete Remission Following Combination Chemotherapy for Metastatic Breast Cancer. J. Clin. Oncol. 1996; 14: 2197–2205
   PubMed Web of Science ®Google Scholar
• Biologic Rhythms in Clinical and Laboratory Medicine, B.K. Rimer, J.R. Harris, M.E. Lippman, M. Morrow, S. Hellman. Springer-Verlag, Berlin 1992
   Google Scholar
• Handbook of Experimental Pharmacology, B.K. Rimer, J.R. Harris, M.E. Lippman, M. Morrow, S. Hellman. Springer, Berlin 1997
   Google Scholar
• Circadian Chronotherapy: From Animal Experiments to Human Cancer Chemotherapy. Chronopharmacology: Cellular and Biochemical Interactions, B.K. Rimer, J.R. Harris, M.E. Lippman, M. Morrow, S. Hellman. Dekker, New York 1989; 439–473
   Google Scholar
• Hrushesky B.W., Bjarnason G.A. Circadian Cancer Therapy. J. Clin. Oncol. 1993; 11: 1403–1417
   PubMed Web of Science ®Google Scholar
• Lévi F., Zidani R., Vannetzel J.M., Perpoint B., Focan C., Faggiuolo R., Chollet P., Garufi C., Itzhaki M., Dogliotti L., Iacobelli S., Adam R., Kunstlinger F., Gastiaburu J., Bismuth H., Jasmin C., Misset J.L. Chronomodulated Versus Fixed Infusion Rate Delivery of Ambulatory Chemotherapy with Oxaliplatin, Fluorouracil and Folinic Acid (Leucovorin) in Patients with Colorectal Cancer Metastases: A Randomized Multi-Institutional Trial. J. Natl Cancer Inst. 1994; 86: 1608–1617
   PubMed Web of Science ®Google Scholar
• Focan C. Marker Rhythms for Cancer Chronotherapy. From Laboratory Animals to Human Beings. In Vivo 1995; 9(4)283–298
   PubMedGoogle Scholar
• Hrushesky W.J. Cancer Chronotherapy: Is There a Right Time in the Day to Treat?. J. Infus. Chemother. 1995; 5(1)38–43
   PubMedGoogle Scholar
• Focan C. Circadian Rhythms and Cancer Chemotherapy. Pharmacol. Ther. 1995; 67(1)1–52
   PubMed Web of Science ®Google Scholar
• Michael S.D., Kaplan S.B., Macmillan B.T. Peripheral Plasma Concentrations of LH, FSH, Prolactin and GH from Birth to Puberty in Male and Female Mice. J. Reprod. Fertil. 1980; 59(1)217–222
   PubMedGoogle Scholar
• Berger J.J., Daniel C.W. Diurnal Rhythms in Developing Ducts of the Mouse Mammary Gland. J. Exp. Zool. 1982; 224: 115–118
   PubMedGoogle Scholar
• Borst D.W., Mahoney W.B. Diurnal Changes in Mouse Mammary Gland DNA Synthesis. J. Exp. Zool. 1980; 214(2)215–218
   PubMedGoogle Scholar
• Gautherie M., Gros C. Circadian Rhythm Alteration of Skin Temperature in Breast Cancer. Chronobiologia 1977; 4(1)1–17
   PubMedGoogle Scholar
• Mansfield C.M., Carabasi R.A., Wells W., Borman K. Circadian Rhythm in the Skin Temperature of Normal and Cancerous Breasts. Int. J. Chronobiol. 1973; 1(3)235–243
   PubMedGoogle Scholar
• Phillips M.J., Wilson D.W., Simpson H.W., Fahmy D.R., Groom G.V., Phillips M.E., Pierrepoint C.G., Blamey R.W., Halberg F., Griffiths K. Characterisation of Breast Skin Temperature Rhythms of Women in Relation to Menstrual Status. Acta Endocrinol. (Copenh.) 1981; 96(3)350–360
   PubMedGoogle Scholar
• Wilson D.W., Griffiths K., Halberg F., Simpson H.W., Griffiths R., Kemp K.W., Nix A.B., Rowlands R.J. Breast Skin Temperature Rhythms in Relation to Ovulation. Chronobiologia 1983; 10(3)231–243
   PubMedGoogle Scholar
• Badran A.F., Echave Llianos J.M. Persistance of Mitotic Circadian Rhythm of a Transplantable Mammary Carcinoma After 35 Generations: Its Bearing on the Success of Treatment with Endoxan. J. Natl Cancer Inst. 1965; 35: 285–290
   PubMedGoogle Scholar
• Halberg F., Haus E., Cardoso S.S., Scheving L.E., Kuhl J.F., Shiotsuka R., Rosene G., Pauly J.E., Runge W., Spalding J.F., Lee J.K., Good R.A. Toward a Chronotherapy of Neoplasia: Tolerance of Treatment Depends Upon Host Rhythms. Experientia 1973; 29(8)909–934
   PubMedGoogle Scholar
• Mooller U., Bojsen J. Circadian Variations in 32P Uptake of DMBA-Induced Mammary Tumour and Walker Carcinosarcoma in Rats. Br. J. Cancer 1976; 33(6)646–654
   PubMedGoogle Scholar
• Garcia-Sainz M., Halberg F. Mitotic Rhythms in Human Cancer, Reevaluated by Electronic Computer Programs. Evidence for Chronopathology. J. Natl Cancer Inst. 1966; 37(3)279–292
   PubMedGoogle Scholar
• Section 6, Cancer Screening. Cancer, Principles and Practice of Oncology, B.K. Rimer, J.R. Harris, M.E. Lippman, M. Morrow, S. Hellman. 4th Ed., Lippincott, Philadelphia 1993; 21: 564–573
   Google Scholar
• Breast Cancer Screening. Diseases of the Breast, B.K. Rimer, J.R. Harris, M.E. Lippman, M. Morrow, S. Hellman. Lippincott–Raven, Philadelphia 1996; Vol. 8: 307–322
   Google Scholar
• Simpson H.W., Pauson A., Cornelissen G. The Chronopathology of Breast Pre-Cancer. Chronobiologia 1989; 16(4)365–372
   PubMedGoogle Scholar
• van der Pompe G., Antoni M.H., Heijnen C.J. Elevated Basal Cortisol Levels and Attenuated ACTH and Cortisol Responses to a Behavioral Challenge in Women with Metastatic Breast Cancer. Psychoneuroendocrinology 1996; 21(4)361–374
   PubMed Web of Science ®Google Scholar
• Touitou Y., Bogdan A., Levi F., Benavides M., Auzeby A. Disruption of the Circadian Patterns of Serum Cortisol in Breast and Ovarian Cancer Patients: Relationships with Tumour Marker Antigens. Br. J. Cancer 1996; 74(8)1248–1252
   PubMed Web of Science ®Google Scholar
• Akbulut H., Icli F., Buyukcelik A., Akbulut K.G., Demirci S. The Role of Granulocyte-Macrophage-Colony Stimulating Factor, Cortisol, and Melatonin in the Regulation of the Circadian Rhythms of Peripheral Blood Cells in Healthy Volunteers and Patients with Breast Cancer. J. Pineal Res. 1999; 26(1)1–8
   PubMedGoogle Scholar
• Singh R.K., Singh S., Razdan J.L. Circadian Periodicity of Plasma 17-Hydroxycorticosteroids in Advanced Breast Cancer. Prog. Clin. Biol. Res. 1987; 227B: 335–342
   PubMedGoogle Scholar
• Touitou Y., Levi F., Bogdan A., Benavides M., Bailleul F., Misset J.L. Rhythm Alteration in Patients with Metastatic Breast Cancer and Poor Prognostic Factors. J. Cancer Res. Clin. Oncol. 1995; 121(3)181–188
   PubMed Web of Science ®Google Scholar
• Singh R.K., Mahdi A.A., Singh D., Rai S.P., Cornelissen G. Studies on Circadian Periodicity of Plasma 17-Hydroxycorticosteroids (17-OHCS) in Carcinoma of the Breast [Published Erratum Appears in In Vivo 1995 Nov–Dec;9(6):606]. In Vivo 1995; 9(4)279–282
   PubMedGoogle Scholar
• Singh R., Singh R.K., Mahdi A.A., Misra S., Rai S.P., Singh D., Cornelissen G., Halberg F. Studies on Circadian Periodicity of Urinary Corticoids in Carcinoma of the Breast. In Vivo 1998; 12(1)69–73
   PubMedGoogle Scholar
• Sephton S.E., Sapolsky R.M., Kraemer H.C., Spiegel D. Diurnal Cortisol Rhythm as a Predictor of Breast Cancer Survival. J. Natl Cancer Inst. 2000; 92(12)994–1000
   PubMedGoogle Scholar
• Tarquini B., Gheri R., Romano S., Costa A., Cagnoni M., Lee J.K., Halberg F. Circadian Variation of Serum Prolactin and TSH of Women in Health or with Mammary Carcinoma, Fibroadenoma or Fibrocystic Mastopathy. Int. J. Chronobiol. 1980; 7(2)101–115
   PubMedGoogle Scholar
• Touitou Y., Fevre M., Lagoguey M., Carayon A., Bogdan A., Reinberg A., Beck H., Cesselin F., Touitou C. Age- and Mental Health-Related Circadian Rhythms of Plasma Levels of Melatonin, Prolactin, Luteinizing Hormone and Follicle-Stimulating Hormone in Man. J. Endocrinol. 1981; 91(3)467–475
   PubMedGoogle Scholar
• Bartsch C., Bartsch H., Fuchs U., Lippert T.H., Bellmann O., Gupta D. Stage-Dependent Depression of Melatonin in Patients with Primary Breast Cancer. Correlation with Prolactin, Thyroid Stimulating Hormone, and Steroid Receptors. Cancer 1989; 64(2)426–433
   PubMedGoogle Scholar
• Larrad J.A., Caballero A.A., Lopez L.N. Pre- and Postoperative Differences in the Circadian Secretion of Prolactin in Carcinoma of the Human Breast. Rev. Esp. Oncol. 1983; 30(2)139–169
   PubMedGoogle Scholar
• Jager W., Sauerbrei W., Diedrich M., Krempel B., Wildt L. 24-Hour CA 15/3 Serum Concentrations in Patients with Primary and Metastasizing Breast Cancer. Onkologie 1987; 10(5)290–293
   PubMedGoogle Scholar
• Pukkala E., Auvinen A., Wahlberg G. Incidence of Cancer Among Finnish Airline Cabin Attendants, 1967–92. Br. Med. J. 1995; 311(7006)649–652, [see comments]
   PubMedGoogle Scholar
• Wartenberg D., Stapleton C.P. Risk of Breast Cancer Is also Increased Among Retired US Female Airline Cabin Attendants. Br. Med. J. 1998; 316(7148)1902
   PubMedGoogle Scholar
• Lynge E. Risk of Breast Cancer Is also Increased Among Danish Female Airline Cabin Attendants. Br. Med. J. 1996; 312(7025)253
   PubMedGoogle Scholar
• Tynes T., Hannevik M., Andersen A., Vistnes A.I., Haldorsen T. Incidence of Breast Cancer in Norwegian Female Radio and Telegraph Operators. Cancer Causes Control 1996; 7(2)197–204
   PubMed Web of Science ®Google Scholar
• Hahn R.A. Profound Bilateral Blindness and the Incidence of Breast Cancer. Epidemiology 1991; 2(3)208–210, [see comments]
   PubMedGoogle Scholar
• Feychting M., Osterlund B., Ahlbom A. Reduced Cancer Incidence Among the Blind. Epidemiology 1998; 9(5)490–494
   PubMedGoogle Scholar
• Verkasalo P.K., Pukkala E., Stevens R.G., Ojamo M., Rudanko S.L. Inverse Association Between Breast Cancer Incidence and Degree of Visual Impairment in Finland. Br. J. Cancer 1999; 80(9)1459–1460
   PubMedGoogle Scholar
• Erren T.C., Piekarski C. Does Winter Darkness in the Arctic Protect Against Cancer? The Melatonin Hypothesis Revisited. Med. Hypotheses 1999; 53(1)1–5
   PubMedGoogle Scholar
• Ballard T., Lagorio S., De Angelis G., Verdecchia A. Cancer Incidence and Mortality Among Flight Personnel: A Meta-Analysis. Aviat. Space Environ. Med. 2000; 71(3)216–224
   PubMedGoogle Scholar
• Brzezinski A. Melatonin in Humans. N. Engl. J. Med. 1997; 336(3)186–195
   PubMed Web of Science ®Google Scholar
• Stevens R.G., Davis S., Thomas D.B., Anderson L.E., Wilson B.W. Electric Power, Pineal Function, and the Risk of Breast Cancer. FASEB J. 1992; 6(3)853–860
   PubMedGoogle Scholar
• Brainard G.C., Kavet R., Kheifets L.I. The Relationship Between Electromagnetic Field and Light Exposures to Melatonin and Breast Cancer Risk: A Review of the Relevant Literature. J. Pineal Res. 1999; 26(2)65–100
   PubMedGoogle Scholar
• Tamarkin L., Cohen M., Roselle D., Reichert C., Lippman M., Chabner B. Melatonin Inhibition and Pinealectomy Enhancement of 7,12-Dimethylbenz(a)anthracene-induced Mammary Tumors in the Rat. Cancer Res. 1981; 41(11 Pt 1)4432–4436
   PubMed Web of Science ®Google Scholar
• Pearson O.H., Llerena O., Llerena L., Molina A., Butler T. Prolactin-Dependent Rat Mammary Cancer: A Model for Man?. Trans. Assoc. Am. Physicians 1969; 82: 225–238
   PubMedGoogle Scholar
• Nagasawa H., Meites J. Suppression by Ergocornine and Iproniazid of Carcinogen-Induced Mammary Tumors in Rats; Effects on Serum and Pituitary Prolactin Levels. Proc. Soc. Exp. Biol. Med. 1970; 135(2)469–472
   PubMedGoogle Scholar
• Yanai R., Nagasawa H. Inhibition of Mammary Tumorigenesis by Ergot Alkaloids and Promotion of Mammary Tumorigenesis by Pituitary Isografts in Adreno-ovariectomized Mice. J. Natl Cancer Inst. 1972; 48(3)715–719
   PubMedGoogle Scholar
• Welsch C.W., Gribler C. Prophylaxis of Spontaneously Developing Mammary Carcinoma in C3H-HeJ Female Mice by Suppression of Prolactin. Cancer Res. 1973; 33(11)2939–2946
   PubMedGoogle Scholar
• Hill S.M., Blask D.E. Effects of the Pineal Hormone Melatonin on the Proliferation and Morphological Characteristics of Human Breast Cancer Cells (MCF-7) in Culture. Cancer Res. 1988; 48(21)6121–6126
   PubMed Web of Science ®Google Scholar
• Shellard S.A., Whelan R.D., Hill B.T. Growth Inhibitory and Cytotoxic Effects of Melatonin and Its Metabolites on Human Tumour Cell Lines In Vitro. Br. J. Cancer 1989; 60(3)288–290
   PubMedGoogle Scholar
• L'Hermite-Baleriaux M., de Launoit Y. Is Melatonin Really an In Vitro Inhibitor of Human Breast Cancer Cell Proliferation?. In Vitro Cell Dev. Biol. 1992; 28A(9–10)583–584
   PubMedGoogle Scholar
• Papazisis K.T., Kouretas D., Geromichalos G.D., Sivridis E., Tsekreli O.K., Dimitriadis K.A., Kortsaris A.H. Effects of Melatonin on Proliferation of Cancer Cell Lines. J. Pineal Res. 1998; 25(4)211–218
   PubMedGoogle Scholar
• Molis T.M., Spriggs L.L., Hill S.M. Modulation of Estrogen Receptor mRNA Expression by Melatonin in MCF-7 Human Breast Cancer Cells. Mol. Endocrinol. 1994; 8(12)1681–1690
   PubMedGoogle Scholar
• Ram P.T., Yuan L., Dai J., Kiefer T., Klotz D.M., Spriggs L.L., Hill S.M. Differential Responsiveness of MCF-7 Human Breast Cancer Cell Line Stocks to the Pineal Hormone, Melatonin. J. Pineal Res. 2000; 28(4)210–218
   PubMedGoogle Scholar
• Wilson S.T., Blask D.E., Lemus-Wilson A.M. Melatonin Augments the Sensitivity of MCF-7 Human Breast Cancer cells to Tamoxifen In Vitro. J. Clin. Endocrinol. Metab. 1992; 75(2)669–670
   PubMedGoogle Scholar
• Rato A.G., Pedrero J.G., Martinez M.A., del Rio B., Lazo P.S., Ramos S. Melatonin Blocks the Activation of Estrogen Receptor for DNA Binding. FASEB J. 1999; 13(8)857–868
   PubMedGoogle Scholar
• Baldwin W.S., Travlos G.S., Risinger J.I., Barrett J.C. Melatonin Does not Inhibit Estradiol-Stimulated Proliferation in MCF-7 and BG-1 Cells. Carcinogenesis 1998; 19(11)1895–1900
   PubMedGoogle Scholar
• Kothari A., Borges A., Ingle A., Kothari L. Combination of Melatonin and Tamoxifen as a Chemoprophylaxis Against N-Nitroso-N-Methylurea-Induced Rat Mammary Tumors. Cancer Lett. 1997; 111(1–2)59–66
   PubMedGoogle Scholar
• Maestroni G.J., Conti A. Melatonin in Human Breast Cancer Tissue: Association with Nuclear Grade and Estrogen Receptor Status. Lab. Invest. 1996; 75(4)557–561
   PubMedGoogle Scholar
• Blask D.E., Wilson S.T., Zalatan F. Physiological Melatonin Inhibition of Human Breast Cancer Cell Growth In Vitro: Evidence for a Glutathione-Mediated Pathway. Cancer Res. 1997; 57(10)1909–1914
   PubMedGoogle Scholar
• Mediavilla M.D., Cos S., Sanchez-Barcelo E.J. Melatonin Increases p53 and p21WAF1 Expression in MCF-7 Human Breast Cancer Cells In Vitro. Life Sci. 1999; 65(4)415–420
   PubMed Web of Science ®Google Scholar
• Eck-Enriquez K., Kiefer T.L., Spriggs L.L., Hill S.M. Pathways Through Which a Regimen of Melatonin and Retinoic Acid Induces Apoptosis in MCF-7 Human Breast Cancer Cells. Breast Cancer Res. Treat. 2000; 61(3)229–239
   PubMedGoogle Scholar
• Bartsch C., Bartsch H., Jain A.K., Laumas K.R., Wetterberg L. Urinary Melatonin Levels in Human Breast Cancer Patients. J. Neural Transm. 1981; 52(4)281–294
   PubMedGoogle Scholar
• Wetterberg L., Halberg F., Halberg E., Haus E., Kawasaki T., Ueno M., Uezono K., Cornelissen G., Matsuoka M., Omae T. Circadian Characteristics of Urinary Melatonin from Clinically Healthy Young Women at Different Civilization Disease Risks. Acta Med. Scand. 1986; 220(1)71–81
   PubMedGoogle Scholar
• Tamarkin L., Danforth D., Lichter A., DeMoss E., Cohen M., Chabner B., Lippman M. Decreased Nocturnal Plasma Melatonin Peak in Patients with Estrogen Receptor Positive Breast Cancer. Science 1982; 216(4549)1003–1005
   PubMedGoogle Scholar
• Skene D.J., Bojkowski C.J., Currie J.E., Wright J., Boulter P.S., Arendt J. 6-Sulphatoxymelatonin Production in Breast Cancer Patients. J. Pineal Res. 1990; 8(3)269–276
   PubMedGoogle Scholar
• Bartsch C., Bartsch H., Bellmann O., Lippert T.H. Depression of Serum Melatonin in Patients with Primary Breast Cancer Is not Due to an Increased Peripheral Metabolism. Cancer 1991; 67(6)1681–1684
   PubMedGoogle Scholar
• Bartsch C., Bartsch H., Karenovics A., Franz H., Peiker G., Mecke D. Nocturnal Urinary 6-Sulphatoxymelatonin Excretion Is Decreased in Primary Breast Cancer Patients Compared to Age-Matched Controls and Shows Negative Correlation with Tumor-Size. J. Pineal Res. 1997; 23(2)53–58
   PubMedGoogle Scholar
• Cohen M., Lippman M., Chabner B. Role of Pineal Gland in Aetiology and Treatment of Breast Cancer. Lancet 1978; 2(8094)814–816
   PubMed Web of Science ®Google Scholar
• Lerchl A. Flight Attendants, Breast Cancer, and Melatonin. Lancet 1998; 352(9137)1388–1389
   PubMedGoogle Scholar
• Leone A.M., Skene D. Melatonin Concentrations in Pineal Organ Culture Are Suppressed by Sera from Tumor-Bearing Mice. J. Pineal Res. 1994; 17(1)17–19
   PubMedGoogle Scholar
• Cos S., Sanchez-Barcelo E.J. Melatonin, Experimental Basis for a Possible Application in Breast Cancer Prevention and Treatment. Histol. Histopathol. 2000; 15(2)637–647
   PubMedGoogle Scholar
• Perez-Lopez F.R., Guillen V., Hergueta J., Lafarga L., Uurcia M. Chronochemotherapy of N-Nitrosomethylurea-Induced Mammary Tumors in Rats. II. Circadian Treatment with Cyclophosphamide. Rev. Esp. Oncol. 1984; 31(4)583–589
   PubMedGoogle Scholar
• Perez-Lopez F.R., Urcia M., Torralba R., Lafarga L., Leal M.C., Guillen V., Hergueta J. Chronotherapy of Breast Cancer Induced by N-Nitrosomethylurea in the Rat. I. Effect of a High Dose of Cyclophosphamide Administered at 8:00 and 14:00 Hours. Rev. Esp. Oncol. 1984; 31(3)401–407
   PubMedGoogle Scholar
• Von Roemeling R., Hrushesky W.J., Kennedy B.J., Buchwald H. Programmed Automatic FUDR Chronotherapy Improves Therapeutic Index. Surg. Forum 1987; 27: 401–402
   Google Scholar
• Perez-Lopez F.R., Urcia M., Torralba R., Lafarga L., Hergueta J. Effect of Prospidine Administered at Different Times of the Day on the Development and Growth of N-Nitrosomethylurea-Induced Mammary Tumors in Wistar Rats. Cancer Lett. 1984; 24(1)111–118
   PubMedGoogle Scholar
• Halberg F., Nelson W., Levi F., Culley D., Bogden A., Taylor D.J. Chronotherapy of Mammary Cancer in Rats. Int. J. Chronobiol. 1980; 7(2)85–99
   PubMedGoogle Scholar
• Granda T.G., Filipski E., D'Attino R.M., Vrignaud P., Anjo A., Bissery M.C., Lévi F. Experimental Chronotherapy of Mouse Mammary Adenocarcinoma MA13/C with Docetaxel and Doxorubicin as Single Agents and in Combination. Cancer Res. 2001, (Accepted for publication)
   PubMedGoogle Scholar
• Canal P., Sqall A., de Forni M., Chevreau C., Pujol A., Bugat R., Roche H., Oustrin J., Houin G. Chronopharmacokinetics of Doxorubicin in Patients with Breast Cancer. Eur. J. Clin. Pharmacol. 1991; 40(3)287–291
   PubMedGoogle Scholar
• Lévi F., Bailleul F., Metzger G. Adriamycin Chronotherapy of Advanced Breast Cancer with a Programmable Implantable Drug Administration Device (DAD). Preliminary Results. Ann. Rev. Chronopharmacol. 1986; 3: 237–240
   Google Scholar
• Dieras V., Extra J.M., Bellissant E., Espie M., Morvan F., Pierga J.Y., Mignot L., Tresca P., Marty M. Efficacy and Tolerance of Vinorelbine and Fluorouracile Combination as First Line Chemotherapy of Advanced Breast Cancer: Results of a Phase II Study Using a Sequential Group Method. J. Clin. Oncol. 1996; 14: 3097–3104
   PubMed Web of Science ®Google Scholar
• Tampellini M., Filipski E., Lévi F. Circadian Variation of Vinorebine Toxicity in Mice. Chronobiol. Int. 1995; 12: 195–198
   Web of Science ®Google Scholar
• Filipski E., Amat S., Lemaigre G., Vincenti M., Breillout F., Lévi F. Relationship Between Circadian Rhythm of Vinorelbine Toxicity and Efficacy in P388-bearing Mice. J. Pharmacol. Exp. Ther. 1999; 289: 231–235
   PubMedGoogle Scholar